IND filing for protein oncology drug planned in first quarter.

Althea Technologies was awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.

QBI-139 is effective in cancer models against a broad range of solid tumors, according to Quintessence. The company plans to file an IND for QBI-139 in the first quarter. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.

Previous articleTakeda Commits Over $1B for Japanese Rights to Amgen Clinical Candidates
Next articleSatiety Hormone Also Prompts Immune-Cell Development